| Description | This antibody AR3D is a human neutralizing IgG specific for Hepatitis C virus envelope glycoprotein E1 and E2 (HCV E2). It has a neutralization efficiency agaist HCV. This product has been tested using Enzyme-linked immunosorbent assay, Bio-layer interferometry and Neutralization assay. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | HCV |
| Epitope | Antigenic region 3 (a.a. 519-535) |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA; BLI; Neut |
| Application Notes | For ELISA, the titrated Abs in dilution buffer with 1% nonfat dry milk was added to the microwells and incubated for 1 hour at room temperature. For Bio-layer interferometry (BLI), the antibody was performed at about 10 μg /mL in a kinetics buffer. And the antibody was performed at 50 μg/mL in vitro neutralization assay. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | HCV E2 |
| Alternative Name | Hepatitis C virus envelope glycoprotein E2 |
| Research Area | Infectious Disease |
| Related Disease | Liver failure, Hepatocellular carcinoma |
